Investor
Ideas #Potcasts 630, #Cannabis News and #Stocks on the Move-(CSE: $LITE.C)
(CSE: $TRUL.C) (OTCQX: $TCNNF) (TSX: $LABS.TO) (TSXV: $KHRN.V)
Delta, Kelowna, BC, April 5, 2022 (Investorideas.com Newswire), investorideas.com, a global news
source covering leading sectors including marijuana and hemp stocks and its potcast site release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2022/040522-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2022/cannabis-potcasts/04051LITE-TRUL-TCNNF-LABS-KHRN.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
In today’s podcast
we look at a few private and public company announcements.
Trulieve
Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing
cannabis company in the United States, announced the launch of "4.20 for
All" Non-Fungible Tokens (NFTs) Collection. The initial offerings will be
available beginning on April 2, at 1pm EST which is exactly 420 hours prior to
April 20 (4/20), the nationally recognized cannabis holiday. Proceeds from all
Trulieve's NFT sales will benefit a charity.
The first cannabis MSO to enter the
metaverse, Trulieve's "4.20 for All" NFT Collection will be sold on
the OpenSea marketplace and can be viewed at opensea.io/collection/trulieve-420-for-all.
Each NFT features a different hand holding a cannabis product. The campaign
celebrates cannabis' diverse community and culture, which includes all types of
users and products.
This is the first in a series of
4/20 activations to be announced by Trulieve. All proceeds from the "4.20
for All" NFT Collection will be donated to the Last Prisoner Project, a
non-profit organization committed to cannabis criminal justice reform and
helping free the over 40,000 individuals still in prison for non-violent
cannabis convictions.
"Trulieve strives to provide
enhanced experiences for our customers and patients, and that now includes the
metaverse, as we introduce our '4.20 for All' NFT Collection," said Kim Rivers,
CEO of Trulieve. "This is a fun and unique way to amplify Trulieve's
steadfast belief in accessibility and to support the Last Prisoner
Project."
Highlighting some of Trulieve's most
popular products on dispensary shelves, the "4.20 for All" NFT
Collection features 10 different original pieces of digital art. There will be
42 copies of each, which results in 420 total offerings in the collection. Each
NFT will be initially offered at .042 Ethereum and every winner will receive a
premium, personalized physical gift item.
"The campaign connects to the
inclusive, diverse, and celebratory narrative that '4.20 for All'
inspires," said Valda Coryat, Trulieve's Chief Marketing Officer.
"Each illustrated hand is a hand raised supporting accessibility and
social justice. From a chef to a hiker … from a yogi to a musician … from an
astronaut to an alien and, yes, even sasquatch. We expect fans and collectors
will be excited to own these NFTs."
Customers and patients interested in
purchasing can do so without owning cryptocurrency, however they will be
required to create an account with OpenSea and transfer the necessary funds to
their digital wallet.
To learn more about Trulieve's
"4.20 for All" NFT Collection and how to purchase, please visit opensea.io/collection/trulieve-420-for-all.
MediPharm
Labs Corp.
(TSX: LABS) (OTCQX: MEDIF), a pharmaceutical company
specialized in precision-based cannabinoids, announced the expansion of its adult use
wellness product line with the launch of CBG and water-soluble products. As of
today, these new products will be available in Ontario in both retail stores
and on the OCS.ca e-commerce website. MediPharm also has purchase commitments
to distribute the products to the Company's other seven provincial distributors
in the coming months.
Bryan
Howcroft CEO of MediPharm commented, "Over the past 16 months,
MediPharm has formulated several innovative product platforms, launched them
and gained traction in the premium wellness segment of the Canadian market. The
announcement today expands the Company's portfolio to include the first
naturally derived CBG products available to Canadian adult consumers and the only
inhalable CBG option in Canada. With recent investments in sales and marketing
functions demonstrating tangible results, our team will continue to bring
differentiated wellness-focused products to market, and work to grow shelf
presence as the year progresses. We also see a meaningful opportunity to
introduce products such as those launched today into international markets,
leveraging our unique GMP Drug Establishment and Natural Health Product
manufacturing licenses, and existing global distribution partnerships."
MediPharm Labs CBG:CBD 1:2 Advanced Formula oral solution is a high-CBG
formulation, manufactured to stringent pharma-quality standards that brings
customers and patients the highest quality and purity available in the market
today. This full-spectrum formulated oil has a subtle cannabis flavour.
Northbound
CBG:CBD The White and Appalachia vape cartridge is formulated with a
terpene blend dominated by citrus zest and berry aromatic with mild herbal
notes to provide balance. Vaping enables users to experience CBG with a faster
onset that is easier to titrate.
MediPharm is proud to lead the
industry in CBG-dominant options for patients and consumers. CBG is one of the
rarer cannabinoids, and has demonstrated some potential as an antibiotic. An
interdisciplinary team of McMaster researchers, which included MediPharm's
Director of Research and Development, Dr. Tait Gale, found that CBG was not
only antibacterial, but also effective in mice against a resilient family of
bacteria known as methicillin-resistant Staphylococcus aureus
("MRSA"). Discovering that CBG has antibacterial properties was
significant given that the MRSA bacterial strain is a leading cause of
infections worldwide and has become increasingly resistant to antibiotics currently
on the market.[1]
MediPharm is also launching a water
soluble CBN:THC liquid solution, Northbound Night Cap. Northbound Night Cap
utilizes proprietary water-soluble emulsification technology developed in-house
by the MediPharm's Research and Development team. This formulation allows
patients and consumers to add CBN to their favourite food or beverage without
overpowering taste and liquid separation. Using an in-house emulsification
method mitigated the Company's need to purchase or license formulations like many
other cannabis industry beverage brands.
Khiron
Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), the global medical cannabis
leader expanding throughout Latin America and Europe, has published in the international
peer-reviewed journal Frontiers in Pain Research the results of its first clinical study on the
use of medical cannabis prescribed to Colombian patients in treating chronic
pain. This is the largest study of its
kind in Latin America, and the first published clinical evidence on the
effectiveness and safety of Khiron's THC and CBD oil-based cannabis
formulations, the two most prescribed products at Khiron's Zerenia Clinics in
Colombia. This is reassuring data for prescribing physicians and health
insurance providers on the efficacy, safety, and cost-effectiveness of the
Khiron's products to treat chronic pain. Frontiers journals rank among the most
influential in their academic fields based on total citations and ranks as the
3rd most-cited publisher among the 20 largest publishers.
The study, a joint effort by medical
researchers from Khiron Life Sciences and doctors from Zerenia Clinics in
Colombia and Europe, captures patient-reported outcome measures
("PROMS") and adverse effects in a large cohort of 2112 adult
patients diagnosed with chronic pain of diverse etiology. Between May and
September 2021, patients received adjuvant treatment with Khiron's oral
oil-based cannabis formulations at the Latin American Institute of Neurology
and Nervous System (ILANS-Zerenia) in Bogotá, Colombia.
"This study, based on Khiron's
medical products, is critical to reassure physicians and health insurance
providers of the efficacy of medicinal cannabis to treat chronic pain. The
global impact and economic burden of chronic pain in our society, mounting
medical evidence will increase access to cannabinoid-based medicines
worldwide." says Alvaro Torres, Khiron CEO and Director. "The recent
vote in the US House of Representatives promoting medical research on cannabis
clearly shows the pressing need to develop effective and safe cannabis-based
medication for suffering patients worldwide. With this and upcoming studies,
Khiron will continue to stand above in the field of medical research and to
expand the access for patients in those jurisdictions in which we are
present".
Guillermo Moreno-Sanz, the first
author of the study and Global Scientific Director of Khiron Life Sciences
adds, "We believe these findings to be generalizable across patient
populations, considering that our results are extremely well-aligned with those
reported by researchers working with similar clinical populations in nations
with long-standing medicinal cannabis access programs, such as Israel and
Canada."
This study is groundbreaking for
Khiron as most observational and experimental studies investigating the
efficacy of medical cannabis for pain management are of relatively short
duration and use a disparity of cannabinoid-based products, routes of
administration, and dosing regimens. This study is differentiated as it
describes the short-, mid- and long-term efficacy and safety of two
monovarietal formulations containing THC and CBD in different ratios (1:1 and
1:25, respectively), and investigates the contribution of patient's sex, and age.
Most participants were female (76.1%) with an average age of 58.7 years old.
One third of the participants were elderly (>65 years old).
As Khiron continues to expand its
research and business globally through Latin America and Europe, additional
studies are expected to continue to demonstrate the Company's business model,
creating a 360-solution for health care providers, insurance companies, and patients
to benefit from the prescription and positive health outcomes from medical
cannabis.
SPOTLITE360
IOT SOLUTIONS, INC. (CSE: LITE) (OTC: SPLTF) announced that it has executed a master terms
agreement dated March 30, 2022, to create a strategic relationship with American Cannabis Consulting (OTCQB:AMMJ) (ACC) an arm’s length party to the
Company. Denver, Colorado based ACC is a nationally recognized
business-to-business cannabis consulting solutions provider and licensed owner
operator with a number of significant brands and company relationships. As
recently as February 25, 2022, ACC announced a partnership with the Bubba Kush
cannabis brand.
Under the terms of the Master
Agreement, both companies will work together in joint consulting engagements to
leverage their combined strengths. SpotLite360’s recent announcement of
acquiring a majority interest in E3 Service Group, combined with SpotLite360’s
SaaS based technology and ACC's deep history of indoor cannabis cultivation
knowledge can offer best in-class design, build, total cost of ownership,
production and financial returns. SpotLite360’s technology will provide supply
chain transparency including the necessary proof of sustainability claims.
James Greenwell, President and CEO
of SpotLite360, commented, “Our companies’ have a shared vision to assist our
clients’ making data driven decisions - across a sustainable agricultural
supply chain. SpotLite360 looks forward to working together with ACC to deliver
process efficiency, support regulatory and compliance mandates, improves
product quality and provide the consumer with the proof of ESG claims that they
are now demanding. Our engineering designs and supply chain platform will drive
best in class models for optimal agricultural cultivation.”
Both companies are currently working
together on significant customer opportunities in seven (7) different states.
Most projects are new construction opportunities with several in advanced
discussions. Joint announcements are anticipated throughout the remainder of
2022.
Ellis Smith, founder and CEO of ACC,
said, “Investors and operators agree, the future of cultivation is not based on
old school mechanical systems, but technology, IOT, automation and data driven
analytics. We believe consistent and repeatable high-quality product is a
direct result of good design, good engineering, best practices, good systems,
good data and good decisions. Together our companies’ will partner with our
customers for more than a consulting agreement, or a design or an install but
for decades of joint successes.”
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google
Podcasts and most audio platforms available.
